MBCProject_4423_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.370
- ESTROGEN_RESPONSE_EARLY+0.350
- INTERFERON_ALPHA_RESPONSE+0.330
- ESTROGEN_RESPONSE_LATE+0.320
- MYC_TARGETS_V2+0.260
- G2M_CHECKPOINT+0.250
- KRAS_SIGNALING_DN+0.220
- DNA_REPAIR+0.150
- UV_RESPONSE_UP+0.120
- ANGIOGENESIS+0.080
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- TGF_BETA_SIGNALING-0.430
- UV_RESPONSE_DN-0.370
- IL6_JAK_STAT3_SIGNALING-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- ANDROGEN_RESPONSE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- COMPLEMENT-0.240
- ALLOGRAFT_REJECTION-0.230
- INFLAMMATORY_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932834 | — | — | 0.786 |
| 2 | TCGA-94-7033-01A-11R-1949-07 | — | cohortSQ1 | 0.783 |
| 3 | TCGA-PE-A5DC-01A-12R-A27Q-07 | — | B | 0.766 |
| 4 | SRR12202495 | — | — | 0.759 |
| 5 | MNG40 | — | — | 0.733 |
| 6 | TCGA-OR-A5JJ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.720 |
| 7 | MBCProject_6876_T1_RNA | — | B | 0.717 |
| 8 | SRR1797263 | — | cohortSC | 0.699 |
| 9 | MNG1109 | — | — | 0.697 |
| 10 | ULC0564T_S96 | — | cohortA1 | 0.689 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |